• 1. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 2. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 3. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 4. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 5. An amphipathic trans-acting phosphorothioate RNA element delivers an uncharged phosphorodiamidate morpholino sequence in mdx mouse myotubes?
  H. V. Jain,D. Verthelyi,S. L. Beaucage RSC Adv., 2017,7, 42519-42528

Research Briefing on 3-Methyl-1-phenyl-1H-indazole (CAS: 1575-29-7): Recent Advances and Applications

3-Methyl-1-phenyl-1H-indazole (CAS: 1575-29-7) is a heterocyclic compound that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile pharmacological properties. Recent studies have explored its potential as a scaffold for drug development, particularly in the areas of oncology, neurology, and inflammation. This briefing synthesizes the latest findings on this compound, highlighting its mechanisms of action, synthetic pathways, and therapeutic applications.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated that 3-methyl-1-phenyl-1H-indazole exhibits potent inhibitory effects on specific kinase targets involved in cancer cell proliferation. The research team utilized structure-activity relationship (SAR) analysis to optimize the compound's binding affinity, leading to the identification of derivatives with enhanced selectivity and reduced off-target effects. These findings underscore the compound's potential as a lead candidate for kinase inhibitor development.

In addition to its anticancer properties, recent investigations have revealed the neuroprotective effects of 3-methyl-1-phenyl-1H-indazole. A study in ACS Chemical Neuroscience (2024) reported that the compound modulates glutamate receptor activity, suggesting its utility in treating neurodegenerative disorders such as Alzheimer's disease. The study employed in vitro and in vivo models to validate the compound's efficacy in reducing oxidative stress and neuronal apoptosis.

The synthetic accessibility of 3-methyl-1-phenyl-1H-indazole has also been a focus of recent research. A 2024 paper in Organic Letters described a novel, high-yield synthesis route using palladium-catalyzed cross-coupling reactions. This method not only improves the scalability of production but also enables the introduction of diverse functional groups, facilitating the development of tailored derivatives for specific therapeutic applications.

Despite these advancements, challenges remain in the clinical translation of 3-methyl-1-phenyl-1H-indazole-based therapeutics. Pharmacokinetic studies indicate that the compound exhibits moderate bioavailability, necessitating further optimization of its formulation. Ongoing research is exploring nanoparticle-based delivery systems to enhance its solubility and tissue penetration, as reported in a 2024 preprint on bioRxiv.

In conclusion, 3-methyl-1-phenyl-1H-indazole (CAS: 1575-29-7) represents a promising scaffold for drug discovery, with demonstrated efficacy across multiple therapeutic areas. Future research should focus on addressing its pharmacokinetic limitations and expanding its clinical applications through targeted derivative design and advanced delivery technologies.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)